Genmab — September 2019
-
Currently, we model in peak sales potential for each of the projects at half of our Darzalex forecast, but with low probability of success (15-20%) and higher risk-adjusted clinical development costs (70% for progression to Phase II, 28% for progression to Phase III). Collectively, the three projects now account for DKK428 per share of our SOTP-derived share price target of DKK1,587
-
In this update we have also adjusted our modelling of Arzerra in multiple sclerosis on the back of top-line data reported on 30 August. We have increased the probability of success to 85% (65%) but have lowered the royalty rate to 10% (12%), as confirmed by Genmab.
-
Så får I ikke mere
-
Rolig Solsen..Bliv endelig ved med at bringe emnet op.

-
Hertil morgen er vi 37% oppe for de seneste tre år. Det har været en lidt træls periode, men den slags sker nu engang for mange gode selskaber. For Novo har det været det samme. Den aktie er også på vej ud af dødvandet.
-
De tålmodige er ikke sådan at ryste af.

-
tak BiotechPro - interessant at se, at pipelinen langt om længe begynder at blive tillagt noget mere sandsynlighed
-
well - Dara ligger med meget højere sandsynlighed i den her type valuation. Jeg kan næsten kun forestille mig, at CAR bruger samme WACC til DCF - og så bliver dara straffet i udregningerne
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind